You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search


( rit-TUCKS-ee-mab )
New Drug Funding Program
  • Rituximab - Single Agent - Indolent Lymphoma
  • Rituximab - Previously Untreated Chronic Lymphocytic Leukemia
  • Rituximab - Maintenance Treatment - Lymphoma
  • Rituximab - Second Line - Chronic Lymphocytic Leukemia
  • Rituximab - Retreatment - Indolent Lymphoma
  • Rituximab - Aggressive Histology Lymphoma
  • Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
  • Rituximab - HIV-Related, Aggressive Histology, B-cell Lymphoma
  • Rituximab - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia
  • Rituximab - As Part of the MATRix Regimen in Newly Diagnosed, Previously Untreated PCNSL
  • Rituximab - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL
Other Name(s): Rituxan®
Appearance: Clear, colourless solution mixed into larger bags of fluids

You might also be interested in